Richard Hazer

• Head of Business Performance and Launch Exellance, Global Sanofi Gx Division

Quality generics

8th IFCA International Female Care Academy

Prague, April 24-25th 2015

SANOFI GENERICSZentiva member of big Sanofi Gx family

8th IFCA

Winthrop created

to harmonize

Western European

Gx business

Acquisition of

Zentiva a leading

Gx company in

CEE

Acquisition

of Helvepharm

in Switzerland

Acquisition

of Medley

a leading Gx

company in

Brazil

Acquisition

of Kendrick

in Mexico

Joint Venture with

Nichi-Iko leading

Gx player in Japan

Acquisition of

Genfar

a leading Gx

company in

Colombia

Joint Venture

with Globalpharma

in Middle-East

Creation of Sanofi Generics Division

JV

JVJV

Sanofi Generics Division hosting strong, well-

established and recognized brands for Gx

. . . 2008 2009 2010 2011 2012 2013 2014

LATIN AMERICA

EUROPE

AFRICAMIDDLE-EAST

ASIA-PACIFIC

Goa

Lüleburgaz

Campinas

Cali

BucharestPrague HQ

Paris

Villa Rica

Dubai

Santa Maria

Legend: Dedicated Manufacturing SiteGlobal BU Gx team

5 Gx DevelopmentCenters

9Gx Network sites

SANOFI GENERICS Worldwide facts

~1bnBoxes produced and distributed per year

7 000employeesdedicated to Gx business

8th IFCA

EUROPE

LATAM

ITC

NORTH AM.

ASIA

JAPAN & PACIFIC

- IMS data not available

BRCO

UK

FR CZ&SK

DE

RU

ZA

BR (INN)

OUR WORLDWIDE PRESENCEGX MARKET AND SANOFI GX SALES, GROWTH & MARKET SHARE

Source IMS – Q4/2014 MAT - Gx market and Sanofi Gx Sales, Growth & Market ShareSource IMS – Dec 2014 MAT - The ranking of Sanofi Gx in top countries

700molecules

marketed

>200launches*

per year

* New molecule(or combinationof INN) + Dosage form in 1 country

* New molecule (or Combination of INN) + Dosage form in 1 country

8th IFCA

1.8bn€net sales

RO

8th IFCA

1/3of the population

have no access

to healthcare

OUR MISSION

Sanofi Generics strengthens its

commitment to provide patients around

the world with reliable access to

valuable and affordable high-quality,

safe and effective medicines.

The generic drugs have a lower cost than

the original marks and therefore there are

high-quality drugs at affordable prices

for the patients.

In addition to being effective therapies,

generic medicines also play an important

role by enabling health care systems to

invest savings in the development of

future, innovative treatments.

8th IFCA

Zentiva is the key element of Sanofi’s Gx Business

● Reaches out to a populationof over 1 billion patients

● Operates in more than90 countries in Europe,Africa, Eurasia and Middle East

● Sales EUR 1,05 billion in 2014

Over 1 billion

patients

Countries

in Europe, Africa,

Eurasia,

and Middle East

90

8th IFCA

Zentiva sales by therapeutics areas

Regional scope: WE - UK, FR, DE, IT, ES, CH CEE - GR , CZ, SK, PL, HU, BG, RO ITC - TR, RU, ZATop 10 ATC are represented

Zentiva sales in M€ by ATC

11

13

21

44

46

72

74

78

119

159

320

380

Sales MAT Q4/ 2014 M€

Dermatology

Various

Oncology

Hormones

Respiratory

Cardio

Female / Urology

Antiinfectives

Blood

Muscle

Alimentary

CNS

ZENTIVA

MAT Q4/ 2014 M€

1,342

Source: IMS

8th IFCA

8th IFCA

Osteology portfolio

8th IFCA

Thank you for your attention